schizophrenia
Conditions
Interventions
benzodiazepine discontinuation group Benzodiazepine (BZD) was gradually tapered and discontinued. Dosages of antipsychotic drugs, sedative-hypnotics, antidepressants, and mood stabilizers were not
Sponsors
Department of Neuropsychiatry St. Marianna University School of Medicine
Ofuji hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) aged 18 to 59 years 2) receiving a stable dose of a single second-generation antipsychotics (SGA) and receiving a stable dose of concomitant benzodiazepine in the daytime for at least 3 months 3) schizophrenic patients who gave informed consent after the study procedures had been fully explained
Exclusion criteria
Exclusion criteria: 1) comorbid central nervous system disorder 2) meeting DSM-IV-TR criteria for alcohol or other substance dependence 3) meeting DSM-IV-TR criteria for mental retardation 4) taking tricyclic antidepressants 5) treatment with electroconvulsive therapy in the 3 months preceding the study; and 6) inability to understand the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function: Brief Assessment of Cognition in Schizophrenia-Japanese version (BACS-J) | — |
Secondary
| Measure | Time frame |
|---|---|
| Psychopathology: Positive And Negative Syndrome Scale (PANSS), Clinical Global Impression- Severity (CGI-S) Subjective QOL: The Schizophrenia Quality of Life Scale -Japanese version (SQLS-J) Adverse effects: Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) | — |
Countries
Japan
Contacts
Public ContactRei Kitajima
St. Marianna University School of Medicine Department of Neuropsychiatry
Outcome results
None listed